tucaresol: causes a dose-dependent left-shift of the oxygen saturation curve of hemoglobin S by stabilization of its oxy-(R)-conformation; an anti-sickling agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 55223 |
CHEMBL ID | 2104482 |
SCHEMBL ID | 600942 |
MeSH ID | M0165817 |
Synonym |
---|
tucaresol |
4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid |
bw a589c |
benzoic acid, 4-((2-formyl-3-hydroxyphenoxy)methyl)- |
unii-jh368g5b9m |
tucaresol [inn:ban] |
bw-589c |
jh368g5b9m , |
bw 589c |
alpha-(2-formyl-3-hydroxyphenoxy)-p-toluic acid |
589c80 |
589c |
84290-27-7 |
589-c |
CHEMBL2104482 |
benzoic acid, 4-[(2-formyl-3-hydroxyphenoxy)methyl]- |
4-[(2-formyl-3-hydroxy-phenoxy)methyl]benzoic acid |
bwa 589c |
SCHEMBL600942 |
tucaresol [mart.] |
.alpha.-(2-formyl-3-hydroxyphenoxy)-p-toluic acid |
tucaresol [inn] |
XEDONBRPTABQFB-UHFFFAOYSA-N |
4-(2-formyl-3-hydroxyphenoxymethyl) benzoic acid |
4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid |
DTXSID70233247 |
F9994-5209 |
AKOS027327314 |
DB13027 |
4-((2-formyl-3-hydroxyphenoxy)methyl)benzoic acid |
589c; 589c80; bwa 589c |
E78089 |
Q27281503 |
BS-50680 |
4-[(2-formyl-3-hydroxyphenoxy)methyl]-benzoic acid |
4-((2-formyl-3-hydroxyphenoxy)methyl)benzoicacid |
Tucaresol is an orally administered antisickling agent. It increases the oxygen affinity of haemoglobin.
Excerpt | Reference | Relevance |
---|---|---|
"1. Tucaresol is an orally administered antisickling agent which increases the oxygen affinity of haemoglobin. " | ( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995) | 1.18 |
Excerpt | Reference | Relevance |
---|---|---|
" Mean Cmax values in plasma and erythrocytes were 81." | ( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995) | 0.56 |
"There were no significant differences in standard pharmacokinetic parameters between the two occasions but the rate of tucaresol absorption was faster after food intake." | ( Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers. Layton, G; Peck, RW; Posner, J; Wiggs, R; Wootton, R, 1998) | 0.76 |
Excerpt | Reference | Relevance |
---|---|---|
" Tucaresol, which is orally bioavailable and systemically active, enhances CD4 Th-cell and CD8 cytotoxic T-cell responses in vivo and selectively favours a Th1-type profile of cytokine production." | ( Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential. Chen, H; Rhodes, J, 1996) | 1.2 |
The utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy. The acute increase in oxygen affinity is physiologically well-tolerated.
Excerpt | Relevance | Reference |
---|---|---|
" The acute increase in oxygen affinity with tucaresol is physiologically well-tolerated, but the utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy." | ( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995) | 0.82 |
" Due to concerns over the sharp rise in haematocrit in one patient, subsequent cohorts received 300 mg tucaresol daily throughout the dosing period." | ( Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Arya, R; Bellingham, AJ; Posner, J; Rolan, PE; Wootton, R, 1996) | 1.95 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1678657 | Immuno-adjuvant activity in E2deltaTM3-immunized BALB/cj mouse assessed as neutralization of HCV H77 genotype 1a pseudotyped virus particle with pooled immune sera at 1 ug/ml | 2020 | ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12 | Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model. |
AID1755546 | Clearance in human at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755548 | Half life in human plasma at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755540 | Cmax in human erythrocytes at 37 mg/kg, po | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755541 | Cmax in human plasma at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755542 | Tmax in human erythrocytes at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755547 | Half life in human erythrocytes at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755545 | AUC (0 to 24 hrs) in human plasma at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755539 | Ratio of drug level in human erythrocytes to plasma at 20 mg/kg, iv measured over 1 hr | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755544 | AUC (0 to 24 hrs) in human erythrocytes at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
AID1755543 | Tmax in human plasma at 37 mg/kg, po by HPLC method | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (3.85) | 18.7374 |
1990's | 12 (46.15) | 18.2507 |
2000's | 8 (30.77) | 29.6817 |
2010's | 3 (11.54) | 24.3611 |
2020's | 2 (7.69) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.50) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (19.23%) | 5.53% |
Reviews | 4 (15.38%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (65.38%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |